Identification	O
of	O
a	O
novel	O
splice	O
site	O
mutation	O
of	O
CLCN5	B
gene	O
and	O
characterization	O
of	O
a	O
new	O
alternative	O
5	O
'	O
UTR	O
end	O
of	O
ClC-5	B
mRNA	O
in	O
human	O
renal	O
tissue	O
and	O
leukocytes	O
.	O

Mutations	O
in	O
the	O
CLCN5	B
gene	O
have	O
been	O
detected	O
in	O
Dent	O
's	O
disease	O
and	O
its	O
phenotypic	O
variants	O
(	O
X	O
-	O
linked	O
recessive	O
nephrolithiasis	O
,	O
X	O
-	O
linked	O
recessive	O
hypophosphatemic	O
rickets	O
,	O
and	O
idiopathic	O
low	O
-	O
molecular	O
-	O
weight	O
proteinuria	O
of	O
Japanese	O
children	O
)	O
.	O

Dent	O
's	O
disease	O
is	O
a	O
tubular	O
disorder	O
characterized	O
by	O
low	O
-	O
molecular	O
-	O
weight	O
proteinuria	O
,	O
and	O
nephrolithiasis	O
associated	O
with	O
nephrocalcinosis	O
and	O
hypercalciuria	O
.	O

ClC-5	B
is	O
the	O
first	O
chloride	O
channel	O
for	O
which	O
a	O
definitive	O
role	O
in	O
the	O
trafficking	O
and	O
acidification	O
-	O
dependent	O
recycling	O
of	O
apical	O
membrane	O
proteins	O
has	O
been	O
established	O
.	O

In	O
the	O
course	O
of	O
CLCN5	B
SSCP	O
analysis	O
in	O
patients	O
with	O
hypercalciuric	O
nephrolithiasis	O
,	O
we	O
detected	O
a	O
novel	O
mutation	O
at	O
intron	O
2	O
of	O
the	O
CLCN5	B
gene	O
,	O
a	O
T	O
-	O
to	O
-	O
G	O
substitution	O
,	O
located	O
17	O
bp	O
upstream	O
of	O
the	O
AG	O
acceptor	O
siteCLCN5	O
gene	O
,	O
a	O
T	O
-	O
to	O
-	O
G	O
substitution	O
,	O
located	O
17	O
bp	O
upstream	O
of	O
the	O
AG	O
acceptor	O
site	O
.	O

To	O
determine	O
the	O
effect	O
of	O
IVS2	O
-	O
17	O
T	O
>	O
G	O
mutation	O
on	O
the	O
correct	O
splicing	O
of	O
intron	O
2	O
,	O
we	O
studied	O
ClC-5	B
transcripts	O
in	O
a	O
patient	O
's	O
peripheral	O
blood	O
leukocytes	O
by	O
means	O
of	O
quantitative	O
comparative	O
RT	O
/	O
PCR	O
,	O
and	O
found	O
a	O
new	O
ClC-5	B
5	O
'	O
UTR	O
isoform	O
characterized	O
by	O
the	O
untranslated	O
exon	O
1b	O
and	O
by	O
retention	O
of	O
intron	O
1b	O
.	O

This	O
new	O
isoform	O
--	O
isoform	O
B1	O
-	O
-was	O
not	O
correlated	O
with	O
mutation	O
since	O
it	O
was	O
detected	O
also	O
in	O
control	O
leukocytes	O
and	O
in	O
renal	O
tissues	O
of	O
kidney	O
donors	O
,	O
thus	O
confirming	O
its	O
physiological	O
role	O
.	O

By	O
RACE	O
analysis	O
we	O
determined	O
the	O
putative	O
transcriptional	O
start	O
site	O
which	O
is	O
located	O
at	O
intron	O
1a	O
,	O
251	O
nt	O
upstream	O
of	O
the	O
first	O
nucleotide	O
of	O
the	O
untranslated	O
exon	O
1b	O
.	O

ORF	O
analysis	O
revealed	O
that	O
intron	O
1b	O
retention	O
in	O
isoform	O
B1	O
stabilizes	O
the	O
initiation	O
of	O
translation	O
to	O
the	O
AGT	O
at	O
position	O
297	O
of	O
the	O
ClC-5	B
cDNA	O
coding	O
region	O
.	O

TNXB	B
locus	O
may	O
be	O
a	O
candidate	O
gene	O
predisposing	O
to	O
schizophrenia	O
.	O

We	O
report	O
here	O
on	O
the	O
detection	O
of	O
nine	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
near	O
to	O
the	O
NOTCH4	B
locus	O
in	O
the	O
search	O
for	O
schizophrenia	O
susceptibility	O
genes	O
in	O
the	O
class	O
III	O
region	O
of	O
the	O
human	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
.	O

We	O
totally	O
analyzed	O
122	O
family	O
trios	O
recruited	O
in	O
the	O
UK	O
.	O

The	O
TDT	O
analysis	O
demonstrated	O
that	O
of	O
the	O
nine	O
SNPs	O
,	O
three	O
were	O
associated	O
with	O
schizophrenia	O
,	O
including	O
rs1009382	O
(	O
P	O
=	O
0.00047	O
)	O
,	O
rs204887	O
(	O
P	O
=	O
0.007	O
)	O
,	O
and	O
rs8283	O
(	O
P	O
=	O
0.015	O
)	O
.	O

Both	O
rs1009382	O
and	O
rs204887	O
are	O
present	O
in	O
the	O
TNXB	B
locus	O
.	O

The	O
rs1009382	O
is	O
a	O
non	O
-	O
synonymous	O
SNP	O
located	O
in	O
exon	O
23	O
of	O
the	O
gene	O
and	O
its	O
A	O
to	O
G	O
base	O
change	O
causes	O
a	O
Glu2578Gly	O
substitution	O
.	O

The	O
goodness	O
-	O
of	O
-	O
fit	O
test	O
showed	O
that	O
genotypic	O
distribution	O
of	O
rs1009382	O
was	O
deviated	O
from	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
due	O
to	O
homozygote	O
excess	O
in	O
the	O
patient	O
group	O
(	O
P	O
=	O
0.01	O
)	O
,	O
suggesting	O
that	O
a	O
double	O
dose	O
of	O
a	O
genetic	O
risk	O
may	O
be	O
involved	O
.	O

Possibly	O
,	O
rs1009382	O
is	O
a	O
candidate	O
SNP	O
predisposing	O
to	O
a	O
schizophrenic	O
illness	O
.	O

Moreover	O
,	O
the	O
test	O
for	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
between	O
paired	O
SNPs	O
showed	O
that	O
the	O
nine	O
SNPs	O
studied	O
may	O
be	O
in	O
the	O
same	O
LD	O
block	O
with	O
an	O
unexpected	O
pattern	O
as	O
the	O
strength	O
of	O
LD	O
was	O
not	O
correlated	O
with	O
the	O
distance	O
between	O
paired	O
SNPs	O
.	O

The	O
haplotype	O
analysis	O
suggested	O
that	O
there	O
might	O
be	O
more	O
than	O
one	O
disease	O
-	O
related	O
allele	O
located	O
in	O
the	O
class	O
III	O
region	O
of	O
the	O
MHC	O
,	O
and	O
that	O
these	O
alleles	O
possibly	O
confer	O
either	O
susceptibility	O
or	O
resistance	O
to	O
schizophrenia	O
.	O

No	O
association	O
between	O
the	O
APOE	B
gene	O
and	O
autism	O
.	O

Autism	O
is	O
a	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
stereotypic	O
and	O
repetitive	O
behavior	O
and	O
interests	O
,	O
together	O
with	O
social	O
and	O
communicative	O
deficiencies	O
.	O

The	O
results	O
of	O
several	O
genomic	O
screens	O
suggest	O
the	O
presence	O
of	O
an	O
autism	O
susceptibility	O
locus	O
on	O
chromosome	O
19p13.2-q13.4	O
.	O

The	O
apolipoprotein	B
E	I
(	O
APOE	B
)	O
gene	O
on	O
chromosome	O
19	O
encodes	O
for	O
a	O
protein	O
,	O
apoE	B
,	O
whose	O
different	O
isoforms	O
(	O
E2	O
,	O
E3	O
,	O
E4	O
)	O
influence	O
neuronal	O
growth	O
.	O

APOE	B
participates	O
in	O
lipid	O
transport	O
and	O
metabolism	O
,	O
repair	O
,	O
growth	O
,	O
and	O
maintenance	O
of	O
axons	O
and	O
myelin	O
during	O
neuronal	O
development	O
.	O

The	O
APOE	B
protein	O
competes	O
with	O
the	O
Reelin	B
protein	O
for	O
VLDL	O
/	O
APOER2	B
receptor	O
binding	O
.	O

Several	O
studies	O
have	O
reported	O
evidence	O
for	O
an	O
association	O
between	O
autism	O
and	O
the	O
Reelin	B
gene	O
.	O

Based	O
on	O
these	O
data	O
we	O
tested	O
for	O
association	O
between	O
APOE	B
and	O
autism	O
using	O
family	O
-	O
based	O
association	O
methods	O
in	O
a	O
data	O
set	O
of	O
322	O
autism	O
families	O
.	O

Three	O
promoter	O
,	O
one	O
intronic	O
,	O
and	O
one	O
3	O
'	O
UTR	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
APOE	B
gene	O
(	O
-491a	O
/	O
t	O
,	O
-427c	O
/	O
t	O
,	O
-219g	O
/	O
t	O
,	O
113c	O
/	O
g	O
,	O
and	O
5361c	O
/	O
t	O
)	O
as	O
well	O
as	O
the	O
APOE	B
functional	O
polymorphism	O
(	O
E2	O
,	O
E3	O
,	O
E4	O
)	O
were	O
examined	O
and	O
failed	O
to	O
reveal	O
significant	O
evidence	O
that	O
autism	O
is	O
associated	O
with	O
APOE	B
.	O

Polymorphisms	O
in	O
the	O
prion	B
protein	I
gene	O
and	O
in	O
the	O
doppel	B
gene	I
increase	O
susceptibility	O
for	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
.	O

The	O
prion	B
protein	I
gene	O
(	O
PRNP	B
)	O
plays	O
a	O
central	O
role	O
in	O
the	O
origin	O
of	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
(	O
CJD	O
)	O
,	O
but	O
there	O
is	O
growing	O
interest	O
in	O
other	O
polymorphisms	O
that	O
may	O
be	O
involved	O
in	O
CJD	O
.	O

Polymorphisms	O
upstream	O
of	O
PRNP	B
that	O
may	O
modulate	O
the	O
prion	B
protein	I
production	O
as	O
well	O
as	O
polymorphisms	O
in	O
the	O
prion	B
-	I
like	I
doppel	I
gene	O
(	O
PRND	B
)	O
have	O
been	O
studied	O
,	O
with	O
inconsistent	O
findings	O
.	O

We	O
investigated	O
the	O
role	O
of	O
a	O
single	O
-	O
nucleotide	O
polymorphism	O
(	O
SNP	O
1368	O
)	O
located	O
upstream	O
of	O
PRNP	O
and	O
three	O
polymorphisms	O
in	O
PRND	B
(	O
T26	O
M	O
,	O
P56L	O
and	O
T174	O
M	O
)	O
in	O
CJD	O
.	O

The	O
study	O
included	O
a	O
population	O
-	O
based	O
sample	O
of	O
52	O
patients	O
with	O
sporadic	O
CJD	O
and	O
250	O
controls	O
.	O

We	O
analysed	O
our	O
data	O
as	O
single	O
markers	O
and	O
haplotypes	O
.	O

Further	O
,	O
we	O
conducted	O
a	O
meta	O
-	O
analysis	O
on	O
PRND	B
T174	O
M	O
comparing	O
the	O
data	O
of	O
the	O
four	O
studies	O
conducted	O
to	O
date	O
.	O

For	O
SNP	O
1368	O
and	O
PRNP	B
M129V	O
,	O
we	O
found	O
significant	O
evidence	O
for	O
linkage	O
disequilibrium	O
.	O

No	O
evidence	O
was	O
found	O
for	O
a	O
relation	O
of	O
SNP	O
1368	O
to	O
CJD	O
independent	O
of	O
PRNP	B
M129V	O
.	O

We	O
further	O
found	O
a	O
significant	O
increased	O
prevalence	O
of	O
M	O
homozygotes	O
at	O
PRND	B
T174	O
M	O
among	O
sporadic	O
CJD	O
patients	O
,	O
when	O
adjusting	O
the	O
analyses	O
for	O
the	O
other	O
genotypes	O
.	O

In	O
the	O
haplotype	O
analyses	O
,	O
the	O
association	O
was	O
strongest	O
for	O
persons	O
homozygous	O
for	O
PRNP	B
129	O
M	O
and	O
PRND	B
174	O
M	O
(	O
odds	O
ratio	O
4.35	O
,	O
95	O
%	O
confidence	O
interval	O
1.05	O
-	O
8.09	O
;	O
P=0.04	O
)	O
.	O

The	O
meta	O
-	O
analysis	O
on	O
the	O
PRND	B
T174	O
M	O
polymorphism	O
did	O
not	O
show	O
a	O
consistent	O
effect	O
across	O
studies	O
,	O
raising	O
the	O
question	O
as	O
to	O
whether	O
PRND	B
174	O
M	O
is	O
causally	O
related	O
to	O
CJD	O
,	O
or	O
whether	O
the	O
PRND	B
allele	O
is	O
in	O
linkage	O
disequilibrium	O
with	O
another	O
polymorphism	O
related	O
to	O
CJD	O
.	O

Is	O
there	O
a	O
future	O
for	O
TNF	B
promoter	O
polymorphisms	O
?	O

The	O
in	O
vitro	O
study	O
of	O
TNF	B
promoter	O
polymorphism	O
(	O
SNP	O
)	O
function	O
was	O
stimulated	O
by	O
the	O
numerous	O
case	O
-	O
control	O
(	O
association	O
)	O
studies	O
of	O
the	O
polymorphisms	O
in	O
relation	O
to	O
human	O
disease	O
and	O
the	O
appearance	O
of	O
several	O
studies	O
claiming	O
to	O
show	O
a	O
functional	O
role	O
for	O
these	O
SNPs	O
provided	O
a	O
further	O
impetus	O
to	O
researchers	O
interested	O
in	O
the	O
role	O
of	O
TNF	B
in	O
their	O
disease	O
of	O
interest	O
.	O

In	O
this	O
review	O
we	O
consider	O
case	O
-	O
control	O
studies	O
,	O
concentrating	O
on	O
the	O
autoimmune	O
and	O
inflammatory	O
diseases	O
rheumatoid	O
arthritis	O
,	O
multiple	O
sclerosis	O
,	O
ankylosing	O
spondylitis	O
,	O
and	O
asthma	O
,	O
and	O
on	O
infectious	O
diseases	O
including	O
malaria	O
,	O
hepatitis	O
B	O
and	O
C	O
infection	O
,	O
leprosy	O
and	O
sepsis	O
/	O
septic	O
shock	O
.	O

We	O
also	O
review	O
the	O
available	O
evidence	O
on	O
the	O
functional	O
role	O
of	O
the	O
various	O
TNF	B
promoter	O
polymorphisms	O
.	O

In	O
general	O
,	O
case	O
-	O
control	O
studies	O
have	O
produced	O
mixed	O
results	O
,	O
with	O
little	O
consensus	O
in	O
most	O
cases	O
on	O
whether	O
any	O
TNF	B
polymorphisms	O
are	O
actually	O
associated	O
with	O
disease	O
,	O
although	O
results	O
have	O
been	O
more	O
consistent	O
in	O
the	O
case	O
of	O
infectious	O
diseases	O
,	O
particularly	O
malaria	O
.	O

Functional	O
studies	O
have	O
also	O
produced	O
mixed	O
results	O
but	O
recent	O
work	O
suggests	O
that	O
the	O
much	O
studied	O
-308G	O
/	O
A	O
polymorphism	O
is	O
not	O
functional	O
,	O
while	O
the	O
function	O
of	O
other	O
TNF	B
polymorphisms	O
remains	O
controversial	O
.	O

Studies	O
of	O
the	O
TNF	B
region	O
are	O
increasingly	O
using	O
extended	O
haplotypes	O
that	O
can	O
better	O
capture	O
the	O
variation	O
of	O
the	O
MHC	O
region	O
.	O

Association	O
of	O
the	O
homeobox	O
transcription	O
factor	O
,	O
ENGRAILED	B
2	I
,	I
3	I
,	O
with	O
autism	O
spectrum	O
disorder	O
.	O

Mouse	O
mutants	O
of	O
the	O
homeobox	O
transcription	O
factor	O
Engrailed2	B
(	O
En2	B
)	O
and	O
autistic	O
individuals	O
display	O
similar	O
cerebellar	O
morphological	O
abnormalities	O
,	O
which	O
include	O
hypoplasia	O
and	O
a	O
decrease	O
in	O
the	O
number	O
of	O
Purkinje	O
cells	O
.	O

Human	O
EN2	B
maps	O
to	O
7q36	O
,	O
a	O
chromosomal	O
region	O
that	O
has	O
demonstrated	O
suggestive	O
linkage	O
to	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
.	O

To	O
investigate	O
EN2	B
for	O
evidence	O
of	O
association	O
with	O
ASD	O
,	O
four	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
(	O
rs3735653	O
,	O
rs1861972	O
,	O
rs1861973	O
,	O
rs2361689	O
)	O
that	O
span	O
the	O
majority	O
of	O
the	O
8.0	O
kb	O
gene	O
were	O
assessed	O
by	O
the	O
transmission	O
/	O
disequilibrium	O
test	O
.	O

Initially	O
,	O
138	O
triads	O
of	O
autistic	O
individuals	O
and	O
their	O
parents	O
were	O
tested	O
.	O

Two	O
intronic	O
SNPs	O
(	O
rs1861972	O
and	O
rs1861973	O
)	O
demonstrated	O
significant	O
association	O
with	O
autism	O
(	O
rs1861972	O
,	O
P=0.0018	O
;	O
rs1861973	O
,	O
P=0.0003	O
;	O
haplotype	O
,	O
P=0.000005	O
)	O
.	O

Flanking	O
exonic	O
SNPs	O
(	O
rs3735653	O
and	O
rs2361689	O
)	O
did	O
not	O
display	O
association	O
.	O

This	O
analysis	O
was	O
then	O
extended	O
to	O
include	O
167	O
small	O
nuclear	O
ASD	O
pedigrees	O
and	O
significant	O
association	O
was	O
again	O
only	O
observed	O
for	O
rs1861972	O
and	O
rs1861973	O
under	O
both	O
the	O
narrow	O
and	O
broad	O
diagnostic	O
criteria	O
(	O
narrow	O
:	O
rs1861972	O
P=0.0290	O
,	O
rs1861973	O
P=0.0073	O
,	O
haplotype	O
P=0.0009	O
;	O
broad	O
:	O
rs1861972	O
P=0.0175	O
,	O
rs1861973	O
P=0.0107	O
,	O
haplotype	O
P=0.0024	O
)	O
.	O

These	O
data	O
demonstrate	O
association	O
between	O
a	O
cerebellar	O
patterning	O
gene	O
and	O
ASD	O
,	O
suggesting	O
a	O
role	O
for	O
EN2	B
as	O
a	O
susceptibility	O
locus	O
and	O
supporting	O
a	O
neurodevelopmental	O
defect	O
hypothesis	O
in	O
the	O
etiology	O
of	O
autism	O
.	O

Binge	O
-	O
eating	O
episodes	O
are	O
not	O
characteristic	O
of	O
carriers	O
of	O
melanocortin-4	B
receptor	O
gene	O
mutations	O
.	O

Recently	O
,	O
Branson	O
and	O
coworkers	O
reported	O
a	O
strong	O
association	O
between	O
binge	O
-	O
eating	O
disorder	O
(	O
BED	O
)	O
and	O
variants	O
in	O
the	O
melanocortin-4	B
receptor	O
gene	O
(	O
MC4R	B
)	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
compared	O
the	O
eating	O
behavior	O
of	O
43	O
obese	O
probands	O
with	O
functionally	O
relevant	O
MC4R	B
mutations	O
and	O
of	O
35	O
polymorphism	O
carriers	O
(	O
V103I	O
or	O
I251L	O
)	O
with	O
wild	O
-	O
type	O
carriers	O
.	O

The	O
module	O
for	O
eating	O
disorders	O
of	O
the	O
Composite	O
International	O
Diagnostic	O
Interview	O
was	O
used	O
to	O
identify	O
binge	O
-	O
eating	O
behavior	O
.	O

The	O
Three	O
-	O
Factor	O
Eating	O
Questionnaire	O
and	O
the	O
Leeds	O
Food	O
Frequency	O
Questionnaire	O
were	O
used	O
to	O
assess	O
restrained	O
eating	O
,	O
disinhibition	O
,	O
hunger	O
and	O
percent	O
total	O
energy	O
intake	O
as	O
fat	O
.	O

No	O
significant	O
differences	O
between	O
carriers	O
of	O
MC4R	B
variants	O
and	O
wild	O
-	O
type	O
carriers	O
were	O
detected	O
.	O

In	O
particular	O
,	O
we	O
found	O
no	O
evidence	O
for	O
an	O
increased	O
rate	O
of	O
binge	O
-	O
eating	O
behavior	O
in	O
obese	O
carriers	O
of	O
MC4R	B
variants	O
.	O

Our	O
findings	O
do	O
not	O
support	O
the	O
strong	O
association	O
between	O
BED	O
and	O
MC4R	B
carrier	O
status	O
.	O

A	O
functional	O
haplotype	O
of	O
the	O
PADI4	B
gene	O
associated	O
with	O
rheumatoid	O
arthritis	O
in	O
a	O
Japanese	O
population	O
is	O
not	O
associated	O
in	O
a	O
United	O
Kingdom	O
population	O
.	O

OBJECTIVE	O
:	O
In	O
the	O
era	O
of	O
postgenomic	O
research	O
,	O
linkage-	O
and	O
association	O
-	O
based	O
strategies	O
are	O
beginning	O
to	O
reveal	O
novel	O
complex	O
disease	O
genes	O
.	O

Using	O
such	O
an	O
approach	O
,	O
a	O
functional	O
haplotype	O
of	O
the	O
peptidylarginine	B
deiminase	I
4	I
gene	O
(	O
PADI4	B
)	O
has	O
recently	O
been	O
identified	O
as	O
a	O
gene	O
conferring	O
susceptibility	O
to	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
in	O
a	O
Japanese	O
population	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
association	O
of	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
PADI4	B
gene	O
with	O
RA	O
in	O
a	O
UK	O
population	O
.	O

METHODS	O
:	O
Association	O
with	O
4	O
exonic	O
SNPs	O
(	O
padi4_89*G	B
/	O
A	O
,	O
padi4_90*T	B
/	O
C	O
,	O
padi4_92*G	B
/	O
C	O
,	O
and	O
padi4_104*T	B
/	O
C	O
)	O
,	O
mapping	O
to	O
the	O
PADI4	B
gene	O
and	O
defining	O
a	O
haplotype	O
previously	O
reported	O
to	O
be	O
associated	O
with	O
RA	O
,	O
was	O
investigated	O
.	O

Genotyping	O
was	O
performed	O
using	O
5	O
'	O
allelic	O
discrimination	O
assays	O
.	O

Estimated	O
haplotypes	O
were	O
generated	O
using	O
the	O
expectation	O
-	O
maximization	O
algorithm	O
,	O
and	O
frequencies	O
of	O
the	O
SNPs	O
and	O
haplotypes	O
were	O
compared	O
between	O
unrelated	O
Caucasian	O
RA	O
patients	O
from	O
the	O
UK	O
(	O
n	O
=	O
839	O
)	O
and	O
population	O
controls	O
(	O
n	O
=	O
481	O
)	O
.	O

RESULTS	O
:	O
Allele	O
frequencies	O
for	O
the	O
4	O
SNPs	O
in	O
the	O
UK	O
population	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
Japanese	O
control	O
population	O
,	O
but	O
none	O
of	O
these	O
was	O
associated	O
with	O
RA	O
.	O

As	O
in	O
the	O
Japanese	O
population	O
,	O
the	O
SNPs	O
in	O
the	O
UK	O
population	O
defined	O
2	O
major	O
haplotypes	O
,	O
but	O
neither	O
was	O
associated	O
with	O
RA	O
(	O
P	O
=	O
0.79	O
)	O
.	O

CONCLUSION	O
:	O
A	O
PADI4	B
susceptibility	O
haplotype	O
associated	O
with	O
RA	O
in	O
a	O
Japanese	O
population	O
is	O
not	O
associated	O
with	O
RA	O
in	O
a	O
UK	O
population	O
.	O

Other	O
genes	O
involved	O
in	O
the	O
citrullinating	O
pathway	O
remain	O
strong	O
candidate	O
RA	O
-	O
susceptibility	O
genes	O
and	O
require	O
further	O
investigation	O
.	O

Extended	O
linkage	O
disequilibrium	O
surrounding	O
the	O
hemoglobin	B
E	I
variant	O
due	O
to	O
malarial	O
selection	O
.	O

The	O
hemoglobin	B
E	I
variant	O
(	O
HbE	B
;	O
(	O
beta	O
)	O
26Glu-->Lys	O
)	O
is	O
concentrated	O
in	O
parts	O
of	O
Southeast	O
Asia	O
where	O
malaria	O
is	O
endemic	O
,	O
and	O
HbE	B
carrier	O
status	O
has	O
been	O
shown	O
to	O
confer	O
some	O
protection	O
against	O
Plasmodium	O
falciparum	O
malaria	O
.	O

To	O
examine	O
the	O
effect	O
of	O
natural	O
selection	O
on	O
the	O
pattern	O
of	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
and	O
to	O
infer	O
the	O
evolutionary	O
history	O
of	O
the	O
HbE	B
variant	O
,	O
we	O
analyzed	O
biallelic	O
markers	O
surrounding	O
the	O
HbE	B
variant	O
in	O
a	O
Thai	O
population	O
.	O

Pairwise	O
LD	O
analysis	O
of	O
HbE	B
and	O
43	O
surrounding	O
biallelic	O
markers	O
revealed	O
LD	O
of	O
HbE	B
extending	O
beyond	O
100	O
kb	O
,	O
whereas	O
no	O
LD	O
was	O
observed	O
between	O
non	O
-	O
HbE	B
variants	O
and	O
the	O
same	O
markers	O
.	O

The	O
inferred	O
haplotype	O
network	O
suggests	O
a	O
single	O
origin	O
of	O
the	O
HbE	B
variant	O
in	O
the	O
Thai	O
population	O
.	O

Forward	O
-	O
in	O
-	O
time	O
computer	O
simulations	O
under	O
a	O
variety	O
of	O
selection	O
models	O
indicate	O
that	O
the	O
HbE	B
variant	O
arose	O
1,240	O
-	O
4,440	O
years	O
ago	O
.	O

These	O
results	O
support	O
the	O
conjecture	O
that	O
the	O
HbE	B
mutation	O
occurred	O
recently	O
,	O
and	O
the	O
allele	O
frequency	O
has	O
increased	O
rapidly	O
.	O

Our	O
study	O
provides	O
another	O
clear	O
demonstration	O
that	O
a	O
high	O
-	O
resolution	O
LD	O
map	O
across	O
the	O
human	O
genome	O
can	O
detect	O
recent	O
variants	O
that	O
have	O
been	O
subjected	O
to	O
positive	O
selection	O
.	O

Pharmacogenetics	O
of	O
the	O
CD14	B
endotoxin	O
receptor	O
polymorphism	O
and	O
progression	O
of	O
coronary	O
atherosclerosis	O
.	O

Atherosclerosis	O
is	O
at	O
least	O
in	O
part	O
an	O
inflammatory	O
disease	O
.	O

CD14	B
is	O
an	O
endotoxin	O
receptor	O
that	O
after	O
binding	O
of	O
lipopolysaccharides	O
evokes	O
endothelial	O
activation	O
and	O
secretion	O
of	O
several	O
cytokines	O
.	O

A	O
polymorphism	O
of	O
CD14	B
has	O
been	O
associated	O
with	O
myocardial	O
infarction	O
.	O

We	O
evaluated	O
the	O
role	O
of	O
the	O
-159	O
T	O
/	O
C	O
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
CD14	B
gene	O
in	O
relation	O
to	O
severity	O
and	O
progression	O
of	O
coronary	O
atherosclerosis	O
and	O
response	O
to	O
the	O
HMG	B
CoA	I
reductase	I
inhibitor	O
pravastatin	O
.	O

We	O
recruited	O
patients	O
from	O
the	O
multi	O
-	O
center	O
double	O
-	O
blind	O
randomized	O
placebo	O
controlled	O
REGRESS	O
trial	O
and	O
genotyped	O
the	O
-159T	O
/	O
C	O
CD14	B
polymorphism	O
.	O

DNA	O
and	O
angiographic	O
follow	O
-	O
up	O
were	O
available	O
from	O
759	O
patients	O
with	O
objectivated	O
coronary	O
artery	O
disease	O
.	O

We	O
measured	O
changes	O
in	O
mean	O
segment	O
diameter	O
(	O
MSD	O
)	O
and	O
minimum	O
obstruction	O
diameter	O
(	O
MOD	O
)	O
with	O
quantitative	O
coronary	O
angiography	O
and	O
noted	O
the	O
occurrence	O
of	O
major	O
adverse	O
cardiac	O
events	O
.	O

The	O
genotype	O
distribution	O
was	O
28	O
%	O
TT	O
,	O
49	O
%	O
CT	O
,	O
23	O
%	O
CC	O
.	O

We	O
did	O
not	O
find	O
any	O
association	O
between	O
genotype	O
and	O
MSD	O
and	O
MOD	O
at	O
baseline	O
,	O
frequency	O
of	O
previous	O
myocardial	O
infarction	O
,	O
changes	O
in	O
MSD	O
and	O
MOD	O
or	O
major	O
clinical	O
events	O
.	O

Treatment	O
with	O
the	O
HMG	B
CoA	I
reductase	I
inhibitor	O
pravastatin	O
reduced	O
progression	O
of	O
coronary	O
atherosclerosis	O
and	O
adverse	O
events	O
equally	O
for	O
all	O
genotypes	O
.	O

We	O
conclude	O
,	O
that	O
the	O
-159T	O
/	O
C	O
polymorphism	O
in	O
the	O
CD14	B
monocyte	O
receptor	O
gene	O
was	O
not	O
associated	O
with	O
progression	O
of	O
coronary	O
atherosclerosis	O
in	O
this	O
population	O
nor	O
did	O
it	O
influence	O
the	O
efficacy	O
of	O
pravastatin	O
in	O
the	O
treatment	O
of	O
atherosclerosis	O
.	O

Evidence	O
for	O
CTLA4	B
as	O
a	O
susceptibility	O
gene	O
for	O
systemic	O
lupus	O
erythematosus	O
.	O

Several	O
lines	O
of	O
evidence	O
implicate	O
the	O
Cytotoxic	B
T	I
Lymphocyte	I
Antigen	I
4	I
(	O
CTLA4	B
)	O
gene	O
in	O
susceptibility	O
to	O
autoimmune	O
disease	O
.	O

We	O
have	O
examined	O
the	O
association	O
of	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
with	O
polymorhisms	O
within	O
the	O
CTLA4	B
gene	O
that	O
were	O
previously	O
proposed	O
to	O
regulate	O
CTLA-4	B
function	O
:	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
position	O
+	O
49	O
of	O
exon	O
1	O
and	O
a	O
dinucleotide	O
repeat	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3'UTR	O
)	O
.	O

The	O
3'UTR	O
repeat	O
showed	O
a	O
significant	O
association	O
with	O
SLE	O
,	O
with	O
one	O
allele	O
conferring	O
susceptibility	O
and	O
another	O
conferring	O
protection	O
to	O
the	O
disease	O
.	O

The	O
associated	O
alleles	O
do	O
not	O
support	O
previous	O
suggestions	O
of	O
an	O
allele	O
size	O
-	O
dependent	O
effect	O
of	O
the	O
3	O
'	O
UTR	O
polymorphism	O
in	O
autoimmunity	O
development	O
and	O
instead	O
suggest	O
that	O
it	O
is	O
in	O
linkage	O
disequilibrium	O
with	O
a	O
true	O
causative	O
locus	O
.	O

No	O
association	O
of	O
the	O
exon	O
1	O
SNP	O
with	O
SLE	O
was	O
found	O
in	O
our	O
population	O
.	O

Given	O
the	O
conflicting	O
results	O
obtained	O
in	O
different	O
studies	O
on	O
the	O
association	O
of	O
SLE	O
with	O
this	O
polymorphism	O
,	O
we	O
performed	O
a	O
meta	O
-	O
analysis	O
including	O
seven	O
previously	O
published	O
studies	O
and	O
the	O
present	O
one	O
.	O

Significantly	O
increased	O
and	O
decreased	O
risks	O
for	O
SLE	O
were	O
found	O
for	O
carriers	O
of	O
the	O
G	O
allele	O
and	O
the	O
A	O
allele	O
,	O
respectively	O
.	O

The	O
functional	O
characterization	O
of	O
disease	O
-	O
associated	O
CTLA4	B
gene	O
variants	O
is	O
now	O
required	O
to	O
elucidate	O
their	O
role	O
in	O
the	O
pathogenesis	O
of	O
SLE	O
and	O
other	O
autoimmune	O
diseases	O
.	O

